The New Jersey Society of Addiction Medicine submitted a letter in support of A3692 which would improve access to MAT, counseling services and withdrawal management services for incarcerated individuals.

ASAM called on the Drug Enforcement Administration (DEA) to finalize its proposed rule to allow Opioid Treatment Programs (OTPs) to operate mobile units without requiring them to obtain a separate registration.

Dr. Yngvild Olsen submitted testimony on the Fiscal Year 2021 LHHS Appropriations Act.

ASAM and the AMA are recommending that states with declared states of emergency request blanket exceptions from the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) that will help patients in an Opioid Treatment Program (OTP) during the COVID-19 pandemic.

LSAM submitted a letter in support of SB213, which would which would require that medical necessity determinations related to substance use disorder (SUD) be made in accordance with the ASAM Criteria by certain insurance policies.

ASAM sent a letter urging key legislators to appropriate funding for programs to bolster the addiction treatment workforce.

Various stakeholders, including Kim Brandt, the Principal Deputy Administrator for Policy & Operations at CMS, and Dr. Shawn Ryan, the chair of ASAM's Legislative Advocacy Committee, testified before the Subcommittee on Health of the Committee on Energy and Commerce.

Dr. Shawn Ryan urges lawmakers to advance bills that would ensure the treatment of addiction is taught, standardized, and covered throughout the United States.